BNT327-01 trial: what clinicians have said so far
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
- NCT06449209 ↗
- Active, not recruiting
- BioNTech SE
- Focused size, estimated: 1–150 verified statements once built
Discussed at: ESMO Congress 2026, SITC 2026
We haven't built an HCP commentary report on BNT327-01 (pumitamig (BNT327) plus carboplatin plus etoposide; pumitamig (BNT327) plus paclitaxel; pumitamig (BNT327) plus topotecan in untreated extensive-stage or previously treated small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BNT327-01 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Extensive-stage Small-cell Lung Cancer; Small-cell Lung Cancer
- Interventions
- BNT327 Dose Level 1 (DL1); BNT327 Dose Level 2 (DL2); Etoposide; Carboplatin; Paclitaxel; Topotecan
- Arms
- Cohort 1 Arm 1 - BNT327 DL1 + carboplatin + etoposide · Experimental
- Cohort 1 Arm 2 - BNT327 DL2 + carboplatin + etoposide · Experimental
- Cohort 2 Arm 1 - BNT327 DL1 + paclitaxel · Experimental
- Cohort 2 Arm 2 - BNT327 DL2 + paclitaxel · Experimental
- Cohort 3 Arm 1 - BNT327 DL1 + topotecan · Experimental
- Cohort 3 Arm 2 - BNT327 DL2 + topotecan · Experimental
- Enrollment
- 110 (estimated)
- Primary outcomes
- Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-related serious adverse events (SAEs) and treatment-related treatment emergent SAEs
- Occurrence of dose interruption, reduction, and discontinuation of study treatment due to TEAEs
- Objective Response Rate
- Best percentage change from baseline in the tumor size
- Proportion of participants who have achieved early tumor shrinkage
- Sponsor
- BioNTech SE
- Start
- Aug 5, 2024
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06449209 · updated Nov 6, 2026